Administration of SP-101 and doxorubicin results in robust and durable hCFTRAR transgene expression in the airways of ferrets

Katherine Excoffon¹, Mark Smith¹, Lillian Falese¹, Robert Schulingkamp¹, Shen Lin¹, Poornima Narayan¹, Madhu Mahankali¹, Matt Glatfelter¹, Eric Yuen¹ and Roland Kolbeck¹

SP-101 – A novel, inhaled AAV-based gene therapy to treat CF

DESIGN FEATURES

- AAV capsid selected for tropism to the apical surface of human airway epithelia (HAE)¹
- hCFTRΔR minigene with regulatory elements^{2,3}

MECHANISM OF ACTION

- Efficient apical entry
- Enhanced SP-101 translocation to the nucleus by administration of doxorubicin (Dox)^{4,5}
- Increased CFTR expression



Ferret as a model to evaluate inhaled SP-101



SP-101 capsid is tropic to ferret airway cells⁶

CF ferret model recapitulates human CF lung pathology⁷

Ability to administer via inhalation



Methods: Non-CF and CF ferrets were exposed to nebulized SP-101 or placebo, followed by doxorubicin (dox) or placebo on Day 1. Animals were necropsied 2 or 12 weeks post-exposure and tissues harvested for in situ hybridization (ISH) or determination of hCFTRAR mRNA copy count. **ISH:** Sections from formalin-fixed, paraffin-embedded lung were evaluated by RNAScope, using zz-probes designed to the sense strand unique regions of the SP-101 vector genome.

hCFTRAR mRNA copies: RNA was isolated, using a DNase procedure to ensure removal of vector genomes, from ~25 mg samples taken from 8-9 different regions of the airway (tracheal, bronchial, lobe). qPCR +/- reverse transcriptase was performed with primers and a probe for a unique region of the *hCFTRAR* mRNA. No signal was observed in the absence of reverse transcriptase indicating the complete removal of vector genomes (data not shown). Data are shown as box and whisker plots around the median value ($hCFTR\Delta R$ copy count normalized to 500ng total RNA).

rovant

REFERENCES: 1. Excoffon KJ, et al. Proc Natl Acad Sci U S A. 2009;106(10):3865-3870. 2. Ostedgaard LS, et al. Proc Natl Acad Sci U S A. 2002;99(5):3093-3098. 3. Yan Z, et al. Hum Gene Ther. 2015;26(6):334-346. 4.Yan Z, et al. J Virol. 2004;78(6):2863-2874. 5. Zhang LN, et al. Mol Ther. 2004;10(6):990-1002. 6. Tang Y, et al. Mol Ther Methods Clin Dev. 2020;19:186-200. 7. Sun X, et al. Sci Transl Med. 2019;11(485):eaau7531.

SP-101 is tropic to the ferret airway







A) hCFTRAR mRNA expression is increased >10 fold by administration of doxorubicin and is durable in non-CF ferret lungs. In contrast to control samples, hCFTRAR mRNA was detected in the majority of samples from animals exposed to SP-101 alone. However, hCFTRAR mRNA was >10-fold higher in samples from animals exposed to the same amount of SP-101 followed by dox (p<0.0001). Moreover, hCFTRΔR mRNA did not significantly decrease (NS) 12 weeks (end of study) post-administration, indicating durable expression. B) hCFTRAR mRNA expression is similar in the lungs of CF and non-CF ferrets. In contrast to control animals (diluent only), hCFTRAR mRNA was detectable to a similar extent in both CF (G551D) and non-CF animals suggesting that the CF lung is not an additional barrier to SP-101.